• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Bone Health and Osteoporosis Foundation
  • Product
    • How it Works
    • The Benefits
    • Warranty and Rental Program
    • Patents & Intellectual Property
    • Order Now
  • Research
  • Testimonials
  • About
    • Mission, History and Values
    • Medical / Scientific Advisors
    • Executive Team
  • Home
  • Blog
  • FAQ
  • Contact
    • Try a Juvent for FREE
  • Shop Now
  • 1.877.758.8368

Moving toward a prevention strategy for osteoporosis by giving a voice to a silent disease

March 7, 2016 Leave a Comment

Moving toward a prevention strategy for osteoporosis by giving a voice to a silent disease.


Women’s Midlife Health
 2016, 2:3  doi:10.1186/s40695-016-0016-0

Abstract

A major unmet challenge in developing preventative treatment programs for osteoporosis is that the optimal timing of treatment remains unknown. In this commentary we make the argument that the menopausal transition (MT) is a critical period in a woman’s life for bone health, and that efforts aimed at reducing fracture risk later in life may benefit greatly from strategies that treat women earlier with the intent of keeping bones strong as long as possible. Bone strength is an important parameter to monitor during the MT because engineering principles can be applied to differentiate those women that maintain bone strength from those women that lose bone strength and are in need of early treatment. It is critical to understand the underlying mechanistic causes for reduced strength to inform treatment strategies. Combining measures of strength with data on how bone structure changes during the MT may help differentiate whether a woman is losing strength because of excessive bone resorption, insufficient compensatory bone formation, trabeculae loss, or some combination of these factors. Each of these biomechanical mechanisms may require a different treatment strategy to keep bones strong. The technologies that enable physicians to differentially diagnose and treat women in a preventive manner, however, have lagged behind the development of prophylactic treatments for osteoporosis. To take advantage of these treatment options, advances in preventive treatment strategies for osteoporosis may require developing new technologies with imaging resolutions that match the pace by which bone changes during the MT and supplementing a woman’s bone mineral density (BMD)-status with information from engineering-based analyses that reveal the structural and material changes responsible for the decline in bone strength during the menopausal transition.

Keywords: Menopausal transition, Bone, Strength, BMD, Osteoporosis, Biomechanics

GDE Error: Error retrieving file - if necessary turn off error checking (404:Not Found)

 

Categories: Uncategorized

Reader Interactions

Leave a Comment Cancel

Footer

  • Home
  • User Testimonials
  • Medical Research
  • Contact
  • FAQs
  • Order Now
  • About
  • Benefits
  • Press
  • Blog
  • Privacy Policy

 


 

In the US it is considered investigational for the treatment of osteoporosis or improvement/maintenance of bone mineral density and our claims have not been reviewed or cleared by the FDA to treat any disease or condition. (2) Calculated over the 20+ year expected life of a Juvent. The JUVENT® Micro-Impact Platform® is Registered as a Class I medical device for exercise and rehabilitation. JUVENT products are covered by the following issued patents, pending patents and their foreign equivalents: 6,843,776 6,884,2277,094211 7,207,954 7,207,955 7,985,191 8,114,036 11/369,611 11/486,538. Juvent, Dynamic Motion Therapy, Micro-Impact Platform, and the symbol are Registered trademarks of Regenerative Technologies Corporation.

Juvent Clinical Studies Request

We protect and keep any given information confidentially.
  • This field is for validation purposes and should be left unchanged.

Juvent Health E-mail Signup

Get news, product updates and special offers in your inbox each month for free!

  • This field is for validation purposes and should be left unchanged.